Max-3 is under clinical development by Maxinovel Pharmaceuticals and currently in Phase I for Alopecia Areata. According to GlobalData, Phase I drugs for Alopecia Areata does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Max-3 LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Max-3 overview

Max-3 is under development for the treatment of alopecia areata and atopic dermatitis. The drug candidate is administered by the topical route. It acts by targeting Janus kinase (JAK) and non-receptor tyrosine-protein kinase (TYK2).

Maxinovel Pharmaceuticals overview

Maxinovel Pharmaceuticals is a biotechnology company that specializes in disease areas characterized by high mortality and high morbidity with no effective treatment. The company is headquartered in China.

For a complete picture of Max-3’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.